Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 20, 2009, Pages 5931-5935

  Chu, Guo Hua ^a   Saeui, Christopher T ^a   Worm, Karin ^a   Weaver, Damian G ^a   Goodman, Allan J ^a   Broadrup, Robert L ^a   Cassel, Joel A ^a   DeHaven, Robert N ^a   LaBuda, Christopher J ^a   Koblish, Michael ^a   Brogdon, Bernice ^a   Smith, Steve ^a   Bourdonnec, Bertrand Le ^a   Dolle, Roland E ^a  

^a ADOLOR CORPORATION   (United States)

Author keywords

Cannabinoid receptors; Pain; Pyridine derivatives; Selective CB2 agonists

Indexed keywords

(MORPHOLINOMETHYL)ANILINE CARBOXAMIDE DERIVATIVE; 2,2 DIMETHYL N [5 METHYL 4 (MORPHOLINOMETHYL)PYRIDIN 2 YL]BUTANAMIDE; BENZENE DERIVATIVE; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; PYRIDINE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PROTEIN BLOOD LEVEL; RECEPTOR BINDING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; DOGS; HUMANS; MALE; MICROSOMES, LIVER; MORPHOLINES; PAIN; PROTEIN BINDING; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 70349220863     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.08.063     Document Type: Article

References (13)

1. Pan H.-L., Wu Z.-Z., Zhou H.-Y., Chen S.-R., Zhang H.-M., and Li D.-P. Pharmacol. Ther. 117 (2008) 141
2. Malan Jr. T.P., Ibrahim M.M., Lai J., Vanderah T.W., Makriyannis A., and Porreca F. Curr. Opin. Pharmacol. 3 (2003) 62
3. Ermann M., Riether D., Walker E.R., Mushi I.F., Jenkins J.E., Noya-Marino B., Brewer M.L., Taylor M.G., Kahrs A.F., Ebneth A., Lobbe S., O'Shea K., Shih D.-T., and Thomson D. Bioorg. Med. Chem. Lett. 18 (2008) 1725
4. Giblin G.M.P., O'Shaughnessy C.T., Naylor A., Mitchell W.L., Eatherton A.J., Slingsby B.P., Rawlings D.A., Goldsmith P., Brown A.J., Haslam C.P., Clayton N.M., Wilson A.W., Chessell I.P., Wittington A.R., and Green R. J. Med. Chem. 50 (2007) 2597
5. Hohmann A.G., Farthing J.N., Zvonok A.M., and Makriyannis A. J. Pharmacol. Exp. Ther. 308 (2004) 446
6. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., Davar G., Makriyannis A., Vanderah T.W., Mata H.P., and Malan Jr. T.P. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3093
7. Worm K., Zhou Q.J., Saeui C.T., Green R.C., Cassel J.A., Stabley G.J., DeHaven R.N., Conway-James N., LaBuda C.J., Koblish M., Little P.J., and Dolle R.E. Bioorg. Med. Chem. Lett. 18 (2008) 2830
8. Worm K., Weaver D.G., Green R.C., Saeui C.T., Dulay D.-M.S., Barker W.M., Cassel J.A., Stabley G.J., DeHaven R.N., LaBuda C.J., Koblish M., Brogdan B.L., Smith S.A., and Dolle R.E. Bioorg. Med. Chem. Lett. 19 (2009) 5004
9. Ninomiya K., Shioiri T., and Yamada S. Tetrahedron 30 (1974) 2151
10. 35 S]GTPγS functional binding assay.
11. Obach S.R. Drug Metab. Dispos. 27 (1999) 1350
12. 2) = 470 nM.
13. LaBuda C.J., and Little P.J. J. Neurosci. Methods 144 (2005) 175